Clinical Trial Search

Primary: Overall Survival (OS) — 46.3; 58.1; 52.9 months — p=0.4051

Primary: Number of Participants With no Residual Tumor Following Photodynamic Therapy (PDT) — 22 Participants

Primary: Maximum Tolerated Dose — 8 J/cm2

Primary: Incidence and / or Severity of Oral Mucositis — 19; 3 Grade 3-4 oral mucositis — p=0.05

Primary: Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment — 2.36; 2.83; 1.9; 2.58 unit on histologic grade scale — p=0.048

Primary: Pre-treatment OSCC Morphology and PDPN Expression — 2.8; 3.4; 2.5 score on a scale from 1 to 5 — p=<0.05

Primary: Objective Response Rate Using Pathological Response — 4 Participants

Primary: Number of Participants With 50% Reduction in Tumor Cell Count and Major Pathologic Response — 9; 6 Participants

Primary: Patients' Overall Response — 0; 15; 2; 4 Participants

Primary: Number of Participants With Adverse Events (AEs) — 2; 3; 0; 2 participants

Primary: Concentration of γ-OH-Acr-dGuo, a Major Acrolein-DNA Adduct — 49.7; 67.1; 46.5 10^9 nucleotides/mL

Primary: Pathologic Response. — 25; 2; 4; 4 Participants

Primary: Number of Participants With Severe (Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v. 4.0] Grade 3-5 Oral Mucositis in Patients Treated to a…

Primary: Percentage of Participants With Severe (WHO Grade 3-4) Oral Mucositis — 23 percentage of participants

Primary: Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily…

Primary: Change in IL-2 Levels — 1.8; 4.0; 7.9; 2.1 pg/100 gm protein — p=<0.05

Primary: Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor Responses — 7 Participants

Primary: Oral Cancer-free Survival in Participants Receiving Erlotinib as Compared With the Control Arm or Placebo Group. — 55; 18 Participants

Primary: - To Evaluate the Efficacy of Sulindac in Subjects With Early or Advanced Oral Premalignant Lesion (OPL) by Both Clinical Response (Reduction in Size of All Lesions) and…

Primary: Ratio of MDSC Concentration in the Blood — 0.7680; 0.7919; 0.9876 ratio from baseline

Primary: Relative Percent Change in Total Lesion Area After 6 Months on Study — -20.6; -17.1 percentage change

Primary: Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After…

Primary: Event-free Survival (EFS)- Number of Participants With an Event — 31; 15 Participants

Primary: Severity of Oral Mucositis — 27; 24; 0; 0 Participants — p=<0.05

Primary: Incidence of Severe OM During Radiation Therapy in Subjects Receiving a Cumulative IMRT Dose of at Least 55 Gy — 15; 9; 10; 12 Participants

Primary: Oral Mucositis Severity - WHO Scale — 3; 3; 0; 0 participants

Primary: 2 Year Progression Free Survival After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous…

Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants

Primary: Percentage of Patients Free of Grade 3+ Late Toxicity — 86 percentage of participants

Primary: OMI-20 Total Score Change From Baseline to Day 3 — 0.0; 0.0 score on a scale